½ÃÀ庸°í¼­
»óǰÄÚµå
1690953

¸¸¼º Á¤¸Æ Æó»ö Ä¡·á ½ÃÀå : ½ÃÀå Á¡À¯À² ºÐ¼®, »ê¾÷ µ¿Çâ ¹× Åë°è, ¼ºÀå ¿¹Ãø(2025-2030³â)

Chronic Venous Occlusions Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Mordor Intelligence | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¸¸¼º Á¤¸Æ Æó»ö Ä¡·á ½ÃÀå ±Ô¸ð´Â 2025³â¿¡ 84¾ï 3,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ°í, ¿¹Ãø ±â°£ 2025³âºÎÅÍ 2030³â±îÁö CAGR 6.38%·Î ¼ºÀåÇÒ Àü¸ÁÀ̸ç, 2030³â¿¡´Â 114¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Chronic Venous Occlusions Treatment-Market-IMG1

¸¸¼º Á¤¸Æ Æó»ö Ä¡·á´Â ¸¸¼º Á¤¸Æ ÁúȯÀÇ Ä¡·á¿¡ »ç¿ëµË´Ï´Ù. Á¤¸Æ Æó»öÀº Á¤¸ÆÀÌ Ç÷Àü, ±ÙÀ°, µ¿¸Æ ¹× ±âŸ Á¤¸Æ°ú °°Àº ÁÖº¯ ±¸Á¶¹°¿¡ ÀÇÇØ Æó»ö, ÇùÂø ¹× ¾Ð¹ÚµÇ´Â °ÍÀÔ´Ï´Ù. ±× °á°ú Ç÷¾×ÀÌ ½×ÀÌ°í ¿ª·ùÇÏ¿© ºÎÀ§¿¡ ÅëÁõ°ú º×±â°¡ »ý±é´Ï´Ù.

¼¼°è Á¤¸Æ Æó»ö¼º Áúº´ÀÇ ³ôÀº À¯º´·üÀº ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 5¿ù International Wound Journal¿¡ °ÔÀçµÈ ¿¬±¸¿¡ µû¸£¸é ¸¸¼º Á¤¸Æ ÁúȯÀÇ Æò±Õ À¯º´·üÀº 58.4%, Á¤¸Æ·ùÀÇ À¯º´·üÀº 22.1%¿´½À´Ï´Ù. ÀÌ·¯ÇÑ ¼¼°è ¼öÁØ¿¡¼­ ³ôÀº À¯º´·üÀº ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå ±â¾÷Àº ƯÈ÷ Ç÷°ü Áúȯ Ä¡·á¸¦ À§ÇÑ Àúħ½À ÀåÄ¡ÀÇ Á¦Ç° Æ÷Æ®Æú¸®¿À¸¦ °­È­Çϱâ À§ÇØ Àμö¿Í °°Àº Àü·«Àû ¿òÁ÷ÀÓÀ» Á¡Á¡ °­È­Çϰí ÀÖ½À´Ï´Ù.

¿¹¸¦ µé¾î, 2024³â 5¿ù, Siemens Hertiners´Â ÀÚȸ»çÀÎ VarianÀ» ÅëÇØ Innova BasculerÀÇ Àμö¸¦ °áÁ¤Çß½À´Ï´Ù. ÀÇ·á±â±â ¾÷°è¿¡¼­ À¯¸íÇÑ Innova Vascular»ç´Â Ç÷°ü Áúȯ Ä¡·á¿¡ ƯȭµÈ ÃÖ÷´Ü Àúħ½À ±â±â¸¦ Àü¹®À¸·Î Çϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä Á¦Ç°ÀÎ ¶ó±¸³ª Ç÷Àü Á¦°Å ½Ã½ºÅÛÀº Ź¿ùÇÑ À¯¿¬¼º, ÃßÀû°¡´É¼º, ´Ù¾çÇÑ Å©±â·Î ³ôÀº Æò°¡¸¦ ¹Þ°í ÀÖ½À´Ï´Ù.

ÀÌ·¯ÇÑ Æ¯¼ºÀ» ÅëÇØ ÇコÄɾî Á¦°ø¾÷ü´Â ȯÀÚÀÇ ÇÁ·ÎÆÄÀÏÀ̳ª Ç÷ÀüÀÇ º¯Çü¿¡ °ü°è¾øÀÌ Á¤¸Æ Ç÷Àü »öÀüÁõ¿¡ È¿°úÀûÀ¸·Î ´ëóÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ Àμö¸¦ ÅëÇØ Siemens Hertiners´Â Ç÷Àü Ä¡·á¿¡ ´ëÇÑ Á¦Ç° ¶óÀξ÷À» Å©°Ô °­È­ÇÏ°í ¿¹Ãø ±â°£ µ¿¾È ½ÃÀåÀÌ Å©°Ô ¼ºÀåÇÒ ¹«´ë¸¦ ¸¶·ÃÇß½À´Ï´Ù.

°Ô´Ù°¡ Á¦¾àȸ»ç´Â Á¤¸ÆºÎÀü Ä¡·á¿¡ ´ëÇÑ ÀνÄÀ» ³ôÀ̱â À§ÇÑ ÀÌ´Ï¼ÅÆ¼ºê¸¦ ¼Ö¼±¼ö¹üÇÏ¿© ÃßÁøÇϰí ÀÖÀ¸¸ç, ¿¹Ãø±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 7¿ù, LES LABORATOIRES SERVIER´Â Á¤¸Æ Áúȯ °è¹ß¿¡ ƯȭµÈ Á¾ÇÕÀûÀÎ Ä·ÆäÀÎÀ» Àü°³Çß½À´Ï´Ù. ÇコÄɾî Àü¹®°¡³ª ȯÀÚ¿Í ¹ÐÁ¢ÇÏ°Ô Çù·ÂÇÔÀ¸·Î½á, ȸ»ç´Â Á¤¸ÆºÎÀüÀÇ ÀÌÇØ¸¦ ±í°Ô Çϰí Áõ»ó °ü¸®¸¦ °­È­ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù. Á¦¾à ±â¾÷¿¡ ÀÇÇÑ ÀÌ·¯ÇÑ Çù·ÂÀûÀÎ ³ë·ÂÀº ¾ÕÀ¸·Î ¼ö³â°£ ½ÃÀå ¼ºÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

ÀÌ¿Í °°ÀÌ Á¤¸ÆÁúȯÀÇ ³ôÀº À¯º´·ü, Á¤¸ÆÁúȯ¿¡ ´ëÇÑ ÀǽÄÀÇ °íÁ¶, ½ÅÁ¦Ç° ¹ß¸Å µî »ó¼úÇÑ ¿äÀÎ ´öºÐ¿¡ ½ÃÀåÀÇ ¼ºÀåÀº ±× ´ëºÎºÐÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª Ä¡·á¿Í °ü·ÃµÈ ºñ¿ë°ú À§ÇèÀº ½ÃÀå ¼ºÀåÀ» ¹æÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸¸¼º Á¤¸Æ Æó»ö Ä¡·á ½ÃÀå µ¿Çâ

½ÉºÎÁ¤¸Æ ºÎÀü ºÎ¹®ÀÌ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹Ãø

¸¸¼º Á¤¸Æ Æó»ö Ä¡·á´Â ÁÖ·Î Ç×»ýÁ¦¿Í Ç×ÀÀ°íÁ¦·Î ±¸¼ºµË´Ï´Ù. ÀÌ ¾àÀº Ç÷°ü ³»ÀÇ Ç÷ÀüÀ» ¿¹¹æÇϰųª Ä¡·áÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Ç÷ÀüÀº ³úÁ¹Áß, ½ÉÀå ¸¶ºñ, ½ÉºÎÁ¤¸Æ Ç÷ÀüÁõ, Æó »öÀüÁõ µî ½É°¢ÇÑ À§ÇèÀ» ÃÊ·¡ÇÕ´Ï´Ù. Ç×ÀÀ°íÁ¦´Â Ç÷Àü Çü¼ºÀ» ¿¹¹æÇϰí Ç÷Àü ¿ëÇØÁ¦´Â ±âÁ¸ Ç÷ÀüÀ» ¿ëÇØ½Ãŵ´Ï´Ù.

½ÉºÎÁ¤¸ÆÇ÷ÀüÁõÀÇ °ü¸®¿¡ À¯È¿ÇÑ Ç×ÀÀ°íÁ¦¿¡´Â ¿¡³ì»çÆÄ¸°, ´ÞÅׯď°, ƾÀÚÆÈ¸° µî ÀúºÐÀÚ·® ÇìÆÄ¸°(LMWH)ºÎÅÍ ¹ÌºÐÈ­ ÇìÆÄ¸°(UFH), ÀÎÀÚXa ¾ïÁ¦Á¦, Á÷Á¢ Æ®·Òºó ¾ïÁ¦Á¦, ¿ÍÆÄ¸° µîÀÇ ºñŸ¹Î K ±æÇ×Á¦±îÁö ´Ù¾çÇÑ °ÍÀÌ ÀÖ½À´Ï´Ù

¸¸¼º Á¤¸Æ Æó»ö¿¡ ¸Â´Â »õ·Î¿î °æ±¸ Ç×ÀÀ°íÁ¦ÀÇ Ã¤¿ëÀÌ Áõ°¡Çϰí ÀÖ´Ù´Â °ÍÀÌ ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ µîÀåÀº ½ÃÀå °æÀïÀ» °ÝÈ­½ÃŰ°í ¸¸¼º Á¤¸Æ Æó»ö Ä¡·áÀÇ ºñ¿ëÀ» ³·Ãß´Â ¹æÇâ¿¡ ÀÖ½À´Ï´Ù. ÀÌ ºñ¿ë Àý°¨Àº ȯÀÚÀÇ ÆíÀǼºÀ» ³ôÀ̰í ÀÌ ºÎ¹® ¼ºÀå¿¡ Á÷Á¢ÀûÀÎ ¿µÇâÀ» ¹ÌĨ´Ï´Ù. 2023³â 9¿ù, Fresenius Kabi Canada´Â ¿¡³ì»çÆÄ¸°ÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÎ ELONOXÀÇ °øÀû »óȯ ½ÂÀÎÀ» ij³ª´Ù ÀüÁÖ¿¡¼­ ÃëµæÇß½À´Ï´Ù. ELONOX. ij³ª´Ù º¸°ÇºÎ´Â ELONOX(¿¡³ì»çÆÄ¸° ³ªÆ®·ý)¸¦ ½ÉºÎÁ¤¸Æ Ç÷ÀüÁõÀ» Æ÷ÇÔÇÑ Ç÷Àü »öÀüÁõ ¿¹¹æÁ¦·Î Ưº°È÷ ½ÂÀÎÇß½À´Ï´Ù. º¸°Ç ´ç±¹¿¡ ÀÇÇÑ ÀÌ·¯ÇÑ »óȯÀº Á¢±Ù¼º°ú ÀûÀÀ¼º Çâ»ó¿¡ ±â¿©ÇÏ°í ºÎ¹®ÀÇ ¼ºÀåÀ» ´õ¿í ÃËÁøÇÕ´Ï´Ù.

½ÉºÎÁ¤¸Æ Ç÷ÀüÁõÀ» ´ë»óÀ¸·Î ÇÑ ÀÓ»ó ¿¬±¸¿¡ ´ëÇÑ °ü½É Áõ°¡´Â ºÎ¹® ¼ºÀåÀÇ Áß¿äÇÑ µå¶óÀ̹ö°¡ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Bayer»ç´Â 2024³â 2¿ù Çõ½ÅÀûÀÎ Ç×-a2 Ç×-Çö󽺹Î(Ç×-a2ap) Ç×üÀÎ BAY3018250ÀÇ DVT ȯÀÚ¸¦ ´ë»óÀ¸·Î ÇÑ 2»ó ÀÓ»ó½ÃÇèÀ» ½ÃÀÛÇß½À´Ï´Ù. º» ½ÃÇèÀÇ °á°ú´Â º» Ç×ü°¡ ½ÉÇÑ Áúȯ¿¡ ´ëÇÑ Áß¿äÇÑ Ä¡·á ¼ö´ÜÀÌ µÉ °¡´É¼ºÀ» ³ªÅ¸³»´Â °ÍÀ¸·Î ±â´ëµË´Ï´Ù. ¹ÙÀÌ¿¤Àº ÀÌ °á°ú¸¦ ¹Þ¾Æ DVT ȯÀÚ¸¦ ´ë»óÀ¸·Î ÇÑ ÀÌ Ç×üÀÇ ÀÓ»ó½ÃÇèÀ» ´ÙÀ½ ´Ü°è·Î ÁøÇàÇϰíÀÚ ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ³ë·ÂÀº ȯÀÚ¿¡°Ô À¯¸ÁÇϸç,ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» µÞ¹ÞħÇÕ´Ï´Ù.

µû¶ó¼­ ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ »ó½Â, DVTÀÇ ÀÓ»ó½ÃÇè Áõ°¡, ¹ÙÀ̾îÀÇ ½Å¾à ÀÓ»ó½ÃÇè°ú °°Àº ´ë±â¾÷ÀÇ Àü·«Àû ¿òÁ÷ÀÓ µîÀÇ ¿äÀÎÀÌ °ãÃÄ ÇâÈÄ ¼ö³â°£ ÀÌ ºÎ¹®ÀÇ ´ëÆøÀûÀÎ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.

¿¹Ãø±â°£ Áß¿¡´Â ºÏ¹Ì°¡ ½ÃÀåÀ» µ¶Á¡

ºÏ¹Ì°¡ ¸¸¼º Á¤¸Æ Æó»ö Ä¡·á ½ÃÀåÀ» µ¶Á¡ÇÒ Àü¸ÁÀÔ´Ï´Ù. ÀÌ ½ÃÀåÀº ÷´Ü °Ç°­ °ü¸® ÀÎÇÁ¶ó, ³ôÀº Á¤¸Æ Áúȯ À¯º´·ü, ÀÇ·á±â±â ¹× ÀǾàǰ¿¡ ´ëÇÑ °ß°íÇÑ ±ÔÁ¦ ½ÂÀο¡ ÀÇÇØ Áö¿øµË´Ï´Ù.

ÀÌ Áö¿ª ½ÃÀåÀº Á¤¸Æ ÁúȯÀÇ ³ôÀº À¯º´·ü¿¡ °ßÀÎµÇ¾î ¼ºÀåÀ» ÀÌ·ç°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 4¿ù ¹Ì±¹ ±¹¸³À§»ý¿¬±¸¼Ò(NIH)´Â 2,500¸¸ ¸í ÀÌ»óÀÇ ¹Ì±¹ÀÎÀÌ Á¤¸Æ·ù·Î °íÅëÀ» °Þ°í ÀÖÀ¸¸ç, ±× Áß 600¸¸¸íÀÌ ½ÉÇÑ Á¤¸ÆÁúȯ¿¡ Á÷¸éÇϰí ÀÖ´Ù°í º¸°íÇß½À´Ï´Ù. À̰ÍÀº ¸¸¼º Á¤¸Æ ÁúȯÀÌ ½É°¢ÇÑ °Ç°­ ¹®Á¦ÀÓÀ» µ¸º¸ÀÌ°Ô ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Áúȯ¿¡ ÀÇÇÑ ºÎ´ãÀÇ Áõ´ë°¡ ¸¸¼º Á¤¸Æ Æó»ö Ä¡·áÀÇ º¸±ÞÀ» ÃËÁøÇϰí, ½ÃÀåÀÇ ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

°Ô´Ù°¡ 2023³â 10¿ù¿¡ Koninklijke Philips NV°¡ ºñ¾Ç¼º Àå ´ëÅðºÎ Æó»ö¼º ÁúȯÀ» ´ë»óÀ¸·Î µà¿À Á¤¸Æ ½ºÅÙÆ® ½Ã½ºÅÛÀ» Æò°¡ÇÑ VIVID ½ÃÇè µî ÁøÇàÁßÀÎ ÀÓ»ó½ÃÇèÀÌ ½ÃÀåÀ» ´õ¿í ¹Ð¾î¿Ã¸± °ÍÀÔ´Ï´Ù. Duo Hybrid ½ºÅÙÆ®¿Í Duo Extend ½ºÅÙÆ®·Î ±¸¼ºµÈ Duo ½Ã½ºÅÛÀº Àå ´ëÅð Á¤¸Æ ºÎ¹®ÀÇ ´Ù¾çÇÑ ÇØºÎÇÐÀû ¹× ±â°èÀû ¿ä±¸¿¡ ´ëÀÀÇÕ´Ï´Ù. ÀåºñÀÇ È¿À²¼º°ú ¾ÈÀü¼ºÀ» º¸ÀåÇϱâ À§ÇÑ ÀÌ·¯ÇÑ Å×½ºÆ®´Â ½ÃÀåÀÇ ÇâÈÄ ¼ºÀå¿¡ ¸Å¿ì Áß¿äÇÕ´Ï´Ù.

¶ÇÇÑ ½ÉºÎÁ¤¸ÆÇ÷ÀüÁõ Ä¡·á¿ëÀ¸·Î ¼³°èµÈ Pharmascience Canada»çÀÇ Pms-rivaroxaban°ú °°Àº Á¦³×¸¯ ÀǾàǰÀÇ º¯Á¾ÀÌ 2023³â 11¿ù¿¡ µµÀÔµÊÀ¸·Î½á ½ÃÀåÀÇ Á¢±Ù¼º°ú ÀûÀÀ¼ºÀÌ ³ô¾ÆÁý´Ï´Ù. ÀÌ·¯ÇÑ ½Å¾à Ãâ½Ã´Â ÇâÈÄ ¼ö³â°£ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

½ÉÇ÷°ü Áúȯ°ú Á¤¸Æ ÁúȯÀÇ À¯º´·üÀÌ »ó½ÂÇϰí ÀÖ´Â °Í ¿Ü¿¡ ÁøÇàÁßÀÎ ÀÓ»ó½ÃÇèÀ̳ª Á¦Ç° Ãâ½Ã°¡ ±â¼¼¸¦ ´Ã¸®°í Àֱ⠶§¹®¿¡ ¸¸¼º Á¤¸Æ Æó»ö Ä¡·á ½ÃÀåÀº ¿¹Ãø±â°£ Áß¿¡ Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¸¸¼º Á¤¸Æ Æó»ö Ä¡·á »ê¾÷ °³¿ä

¸¸¼º Á¤¸Æ Æó»ö Ä¡·á ½ÃÀåÀº ¹Ý °íÁ¤ÀûÀÌ¸ç ¿©·¯ ±â¾÷ÀÌ ÀÖ½À´Ï´Ù. ½ÃÀå °³Ã´ ±â¾÷Àº ÇÕº´, Àμö, Á¦ÈÞ, °øµ¿°³¹ß µî ´Ù¾çÇÑ Àü·«À» ±¸»çÇÏ¿© ½Å¾à°ú ½Å µð¹ÙÀ̽º¸¦ °³¹ßÇϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä ÁøÃâ±â¾÷À¸·Î´Â Cardinal Health, Stryker, Cook Medical, Boston Scientific Corporation, Edward Lifesciences, AngioDynamics µîÀÌ ÀÖ½À´Ï´Ù.

±âŸ ÇýÅà :

  • ¿¢¼¿ Çü½Ä ½ÃÀå ¿¹Ãø(ME) ½ÃÆ®
  • 3°³¿ù°£ÀÇ ¾Ö³Î¸®½ºÆ® ¼­Æ÷Æ®

¸ñÂ÷

Á¦1Àå ¼­·Ð

  • Á¶»ç ÀüÁ¦Á¶°Ç ¹× ½ÃÀå Á¤ÀÇ
  • Á¶»ç ¹üÀ§

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå ¿ªÇÐ

  • ½ÃÀå °³¿ä
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • °íµµÀÇ Ä¡·á¹ý ¹× ÀåÄ¡ °¡¿ë¼º Áõ°¡
    • Á¤¸Æ Æó»ö¼º ÁúȯÀÇ À¯º´·ü Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • Ä¡·á¿¡ µû¸¥ À§ÇèÀ̳ª ÇÕº´Áõ°ú ¿¬°üµÈ ºñ¿ë ÀǽÄ
  • Porter's Five Forces ºÐ¼®
    • ½Å±Ô Âü°¡¾÷üÀÇ À§Çù
    • ±¸¸ÅÀÚ ¹× ¼ÒºñÀÚÀÇ Çù»ó·Â
    • °ø±Þ±â¾÷ÀÇ Çù»ó·Â
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀï °ü°èÀÇ °­µµ

Á¦5Àå ½ÃÀå ¼¼ºÐÈ­

  • Ä¡·á À¯Çüº°
    • ¸¸¼º ½ÉºÎÁ¤¸ÆÇ÷ÀüÁõ
    • ÇÏÁöÁ¤¸Æ·ù
    • ½ÉºÎÁ¤¸ÆºÎÀü
    • ±âŸ Ä¡·á À¯Çü
  • Á¦Ç° À¯Çüº°
    • µð¹ÙÀ̽º
    • Ä¡·áÁ¦
  • Áö¿ªº°
    • ºÏ¹Ì
      • ¹Ì±¹
      • ij³ª´Ù
      • ¸ß½ÃÄÚ
    • À¯·´
      • µ¶ÀÏ
      • ¿µ±¹
      • ÇÁ¶û½º
      • ÀÌÅ»¸®¾Æ
      • ½ºÆäÀÎ
      • ±âŸ À¯·´
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
      • Áß±¹
      • ÀϺ»
      • Àεµ
      • È£ÁÖ
      • Çѱ¹
      • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
      • GCC
      • ³²¾ÆÇÁ¸®Ä«
      • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¹Ì
      • ºê¶óÁú
      • ¾Æ¸£ÇîÆ¼³ª
      • ±âŸ ³²¹Ì

Á¦6Àå °æÀï ±¸µµ

  • ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Cardinal Health
    • Stryker
    • Cook Medical
    • Boston Scientific Corporation
    • Edward Lifesciences
    • AngioDynamics
    • SIGVARIS GROUP
    • Johnson & Johnson Inc.(Janssen Global Services LLC)
    • Penumbra Inc.
    • Becton, Dickinson and Company

Á¦7Àå ½ÃÀå ±âȸ ¹× ÇâÈÄ µ¿Çâ

AJY 25.04.09

The Chronic Venous Occlusions Treatment Market size is estimated at USD 8.43 billion in 2025, and is expected to reach USD 11.48 billion by 2030, at a CAGR of 6.38% during the forecast period (2025-2030).

Chronic Venous Occlusions Treatment - Market - IMG1

Chronic venous occlusion treatment is used to treat chronic venous diseases. Venous occlusion is when veins are blocked, narrowed, or compressed by nearby structures such as clots, muscles, arteries, or other veins. This can result in blood pooling and flowing backward, causing pain and swelling in the area.

The high prevalence of venous occlusion diseases globally drives the market's growth. For instance, a study published in the International Wound Journal in May 2024 revealed that the mean prevalence of chronic venous diseases was 58.4%, and the prevalence of varicose veins was 22.1%. Such a high prevalence of disease at the global level propels the market's growth.

Major market players are increasingly making strategic moves, such as acquisitions, to bolster their product portfolios, particularly in minimally invasive devices for vascular disease treatment.

For instance, in May 2024, Siemens Healthineers, through its subsidiary Varian, finalized the acquisition of Innova Vascular. Innova Vascular, a prominent player in the medical device industry, specializes in cutting-edge, minimally invasive devices tailored for vascular disease treatment. The flagship product, the Laguna Thrombectomy System, is lauded for its exceptional flexibility, trackability, and diverse range of sizes.

These attributes enable healthcare providers to address venous thromboembolism across patient profiles and clot variations effectively. With this acquisition, Siemens Healthineers has significantly bolstered its offerings for blood clot treatments, setting the stage for substantial growth in this market during the forecast period.

Additionally, pharmaceutical companies are increasingly spearheading initiatives to raise awareness about treating venous insufficiency to propel market growth during the forecast period. For example, in July 2023, LES LABORATOIRES SERVIER rolled out a comprehensive campaign dedicated to venous disease awareness. By closely collaborating with healthcare professionals and patients, the company aims to deepen the understanding of venous insufficiency and enhance symptom management. These concerted efforts from pharmaceutical entities are poised to drive market growth in the coming years.

Thus, owing to the abovementioned factors, such as the high prevalence of venous diseases, increasing awareness of venous diseases, and the launch of new products, the growth of the market is the majority driving it. However, the cost compilations and risk associated with treatment may hinder the growth of the market.

Chronic Venous Occlusions Treatment Market Trends

The Deep Vein Insufficiency Segment is Expected to Drive the Market Growth During the Forecast Period

Chronic venous occlusion treatment therapeutics primarily consist of antibiotics and anticoagulants. These medications aim to either prevent or treat blood clots within blood vessels. Such clots pose severe risks, including stroke, heart attack, deep vein thrombosis, and pulmonary embolism. Anticoagulants prevent clot formation, while thrombolytics dissolve existing clots.

Effective anticoagulants for managing deep venous thrombosis encompass a range, from low molecular weight heparins (LMWHs) like enoxaparin, dalteparin, and tinzaparin to unfractionated heparin (UFH), factor Xa inhibitors, direct thrombin inhibitors, and vitamin K antagonists such as warfarin.

The segment's growth is propelled by the rising adoption of new oral anticoagulants tailored for chronic venous occlusion.

The advent of biosimilars is poised to intensify market competition, driving down the costs of chronic venous occlusion drugs. This cost reduction enhances patient accessibility, directly influencing the segment's growth. In September 2023, Fresenius Kabi Canada achieved public reimbursement approval for ELONOX, its enoxaparin biosimilar, across all Canadian provinces. ELONOX. Health Canada specifically endorsed ELONOX (enoxaparin sodium) for thromboembolic disorder prophylaxis, including deep vein thrombosis. Such reimbursement by health authorities contributes to increased accessibility and adaptability and further propels segmental growth.

The increasing focus on clinical studies targeting deep vein thrombosis is anticipated to be a significant driver for segmental growth. A case in point is Bayer AG, which, in February 2024, initiated a Phase II clinical trial for BAY3018250, an innovative anti-a2 antiplasmin (anti-a2ap) antibody, in DVT patients. The trial's results are expected to highlight the antibody's potential as a crucial treatment avenue for severe medical conditions. Buoyed by these findings, Bayer is keen to advance the antibody to the next phase of clinical trials, with a specific focus on DVT patients. Such initiatives hold promise for patients and bolster the segment's growth.

Therefore, the confluence of factors, including the rise of biosimilars, an uptick in clinical studies for DVT, and strategic moves by major players, like Bayer's new drug trials, is poised to drive significant growth in the segment in the coming years.

North America Dominates the Market During the Forecast Period

North America is poised to dominate the chronic venous occlusion treatment market. It is buoyed by its advanced healthcare infrastructure, high venous disease prevalence, and robust regulatory approvals for medical devices and drugs.

The region's market is witnessing growth, driven by the high prevalence of venous diseases. For instance, in April 2023, the National Institutes of Health (NIH) reported that over 25 million Americans suffer from varicose veins, with a staggering 6 million facing severe venous disease. This highlights the gravity of chronic venous conditions as a significant health concern. The rising burden of these conditions has driven the adoption of chronic venous occlusion treatments, fueling market growth.

Moreover, ongoing clinical trials, such as the VIVID trial in October 2023, which assessed the Duo venous stent system by Koninklijke Philips N.V. for nonmalignant iliofemoral occlusive disease, are set to propel the market further. The Duo system, comprising the Duo Hybrid and Duo Extend stents, caters to the diverse anatomical and mechanical needs of the iliofemoral venous segment. These trials to ensure device efficacy and safety are pivotal for the market's future growth.

Also, the introduction of generic drug variants, like Pharmascience Canada's Pms-rivaroxaban in November 2023, designed for deep vein thrombosis treatment, enhances market accessibility and adaptability. Such launches will drive the market's growth in the coming years.

Given the rising prevalence of cardiovascular and venous diseases, alongside the momentum from ongoing clinical trials and the launch of products, the chronic venous occlusion treatment market is set for substantial growth during the forecast period.

Chronic Venous Occlusions Treatment Industry Overview

The chronic venous occlusion treatment market is semi-consolidated, with several players. Companies in the market use diverse strategies such as mergers, acquisitions, partnerships, and collaborations to develop new drugs and devices. Some of the major players in the market include Cardinal Health, Stryker, Cook Medical, Boston Scientific Corporation, Edward Lifesciences, and AngioDynamics.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Availability of Advanced Treatments and Devices
    • 4.2.2 Increasing Prevalence of Venous Occlusion Diseases
  • 4.3 Market Restraints
    • 4.3.1 Cost Consciousness Coupled with Risk and Complications Associated with Treatment
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD)

  • 5.1 By Treatment Type
    • 5.1.1 Chronic Deep Vein Thrombosis
    • 5.1.2 Varicose Veins
    • 5.1.3 Deep Vein Insufficiency
    • 5.1.4 Other Treatment Types
  • 5.2 By Product Type
    • 5.2.1 Devices
    • 5.2.2 Therapeutics
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Cardinal Health
    • 6.1.2 Stryker
    • 6.1.3 Cook Medical
    • 6.1.4 Boston Scientific Corporation
    • 6.1.5 Edward Lifesciences
    • 6.1.6 AngioDynamics
    • 6.1.7 SIGVARIS GROUP
    • 6.1.8 Johnson & Johnson Inc. (Janssen Global Services LLC)
    • 6.1.9 Penumbra Inc.
    • 6.1.10 Becton, Dickinson and Company

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦